Eliem Therapeutics, Inc.

    Jurisdiction
    United States
    ISIN
    US28658R1068 (ELYM)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€98.38M
    EBIT margin
    0.0%
    Net income
    -€44.65M
    Net margin
    0.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    N/A -€45.85M +2.7%
    N/A -€64.39M +40.4%
    N/A -€87.37M +35.7%

    Dividends

    No dividend payouts

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 514K $627.57K +142K Buy

    Add to watchlist

    Notifications